FilingSEC EDGAR6-K
AC Immune Announces Positive Safety and Immunogenicity Results from Phase 2 Trial of ACI-7104
· SEC accepted
StagePhase 2
Filing content
AC Immune reported that its Phase 2 trial of ACI-7104 for Parkinson's disease met all primary endpoints for safety and immunogenicity at week 100.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…